- •Sjögren’s Syndrome
- •Foreword
- •Contents
- •Contributors
- •1.1 Primary Sjögren’s Syndrome
- •1.1.1 Diagnostic Criteria
- •1.1.2 Incidence
- •1.1.3 Prevalence
- •References
- •2.1 Introduction
- •2.2 Genetic Epidemiology of SS
- •2.3 Key Concepts in Genetics, Transcriptomics, and Proteomics
- •2.4 Candidate Genes and SS Pathogenesis
- •2.5 Gene Expression Studies in SS
- •2.6 Protein Expression Studies in SS
- •2.7 Future Directions
- •References
- •3.1 Introduction
- •3.2 Characteristics of Autoimmune Lesions
- •3.3 Epithelial Cells as Key Regulators of Autoimmune Responses
- •3.4 Tissue Injury and Repair
- •3.4.1 Functional Impairment of Glands and Autonomic Nervous System Involvement
- •3.4.2 Extracellular Matrix and Tissue Damage
- •3.5 Pathogenetic Factors
- •3.5.1 Genetic Predisposition
- •3.5.2 Environmental Factors
- •3.5.3 Hormonal
- •3.6 Conclusions/Summary
- •References
- •4.1 Hepatitis C Virus
- •4.2 Hepatitis B Virus
- •4.5 Coxsackieviruses
- •4.6 Herpes Viruses
- •4.7 Human Parvovirus B19
- •4.8 Conclusion
- •References
- •5.1 The Role of T Cells in SjS
- •5.2 The Role of B Cells in SjS
- •5.2.1 The Impact of B Cell Cytokines
- •5.2.2 Ontogeny of B Lymphocytes
- •5.2.3 Subpopulations of B Cells
- •5.2.4 B Cell Monoclonal Expansion
- •5.3 B Cells Are Not Dispensable
- •5.3.1 B Cell Chemokines and Antibody Production
- •5.3.2 Peculiarities of B Cell Products: Cytokines and IgA Autoantibodies
- •5.3.3 Intrinsic Abnormalities of B Cells in Primary SjS
- •5.4 Conclusion
- •References
- •6.1 Introduction
- •6.3 Objective Determination of Salivary Flow
- •6.4 Etiology of Xerostomia
- •6.5 Orofacial Manifestations in SS
- •6.5.1 Salivary Involvement
- •6.5.2 Neurological Involvement
- •6.6 Sialochemical Changes in SS
- •6.7 Hyposalivation: Clinical Features and Complications
- •6.7.1 Clinical Features
- •6.7.2 Examination
- •6.7.3 Clinical Signs of Hyposalivation
- •6.7.4 Effect of Hyposalivation on Quality of Life
- •6.7.5 Management of Hyposalivation
- •6.7.6 Chronic Complications of Hyposalivation
- •Box 6.1: Chronic Complications of Hyposalivation
- •6.7.6.1 Dental Caries
- •Box 6.2: Strategies for Reducing Dental Caries in Patients with Sjögren’s Syndrome
- •6.7.6.2 Periodontal Health
- •6.7.6.3 Oral Functional Impairments
- •6.7.6.4 Oral Infections
- •Box 6.3: Factors Predisposing to Oral Candidiasis
- •6.7.6.6 Angular Stomatitis
- •6.7.6.7 Candidiasis
- •6.7.6.8 Bacterial Sialadenitis
- •6.7.6.9 Oral Ulceration
- •6.8 Salivary Gland Enlargement
- •6.8.1 Box 6.5: Non-Salivary Causes of Salivary Gland Enlargement
- •6.9 Salivary Swelling in SS
- •References
- •Key Websites (Accessed Dec 19, 2009)
- •7.1 Sjögren’s Syndrome: A Disease of the Lacrimal Functional Unit
- •7.2 Components of the Lacrimal Functional Unit
- •7.3 Lacrimal Gland
- •7.4 Conjunctiva
- •7.5 Cornea
- •7.6 Meibomian Glands and Eyelids
- •7.7 Neural Innervation
- •7.8 Mechanisms of Dysfunction
- •7.8.1 Lacrimal Gland
- •7.8.2 Ocular Surface
- •7.9 Diagnosis of Ocular Involvement in Sjögren’s Syndrome
- •7.10 Treatment of LFU Dysfunction
- •References
- •8.1 Introduction
- •8.2 Otologic Manifestations
- •8.3 Sinus and Nasal Manifestations
- •8.4 Laryngopharyngeal and Tracheal Manifestations
- •References
- •9.1 Epidemiology of Fatigue
- •9.2 Assessing Fatigue
- •9.4 Relationship of Fatigue to Cognitive Symptoms and to Depression
- •9.5 Fatigue Viewed From the Physiological Perspective: Relationships Between Fatigue, Sleep Quality, and Neuroendocrine Function
- •9.6 Relationship Between Fibromyalgia and SS
- •9.7 Management of Pain and Fatigue
- •9.8 Summary
- •References
- •10.1 Introduction
- •10.2 Arthralgias and Arthritis
- •10.3 Arthritis: Patterns of Expression
- •10.4 Differential Diagnosis: RA, SLE, and Other Arthropathies
- •References
- •11.1 Introduction
- •11.2 Epidemiology
- •11.3 Skin Changes Encountered in Primary SjS
- •11.3.1 Pruritus
- •11.3.2 Annular Erythema of SjS
- •11.3.3 Eyelid Dermatitis
- •11.3.4 Panniculitis
- •11.3.5 Primary Nodular Cutaneous Amyloidosis
- •11.3.6 B Cell Lymphoma
- •11.4 Skin Changes Encountered in Secondary SjS
- •11.4.1 Skin Changes Associated with Lupus Erythematosus
- •References
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3 Histopathology
- •12.4 Laboratory Findings
- •12.5 Pathogenesis
- •12.6 Clinical Findings
- •12.7 Skin
- •12.8 Peripheral and Central Nervous System
- •12.9 Other Organs
- •12.10 Vasculitis and Mortality
- •12.11 Treatment
- •References
- •13.1 Introduction
- •13.2 Pericarditis
- •13.3 Myocarditis
- •13.4 Valvular Abnormalities
- •13.5 Diastolic Dysfunction
- •13.6 Atrioventricular Block
- •13.7 Subclinical Atherosclerosis
- •13.8 Pulmonary Arterial Hypertension
- •13.9 Autonomic Cardiovascular Dysfunction
- •13.10 Therapeutic Management
- •13.11 Conclusion
- •References
- •14.1 Introduction
- •14.2 Airway Disease
- •14.2.1 Overview
- •14.2.2 Pathology
- •14.2.3 Imaging Studies
- •14.3 Interstitial Lung Disease
- •14.3.1 Overview
- •14.3.2 Pathology
- •14.3.4 Usual Interstitial Pneumonia
- •14.3.5 Follicular Bronchiolitis
- •14.3.6 Lymphocytic Interstitial Pneumonia
- •14.3.7 Cryptogenic Organizing Pneumonia
- •14.3.8 Clinical Features
- •14.3.9 Imaging Studies
- •14.4 Pleuritis
- •14.5 Diagnosis and Management
- •References
- •15.1 Evaluation of the Sjögren’s Syndrome and Raynaud’s Phenomenon
- •15.2 Management of Raynaud’s Phenomenon
- •15.2.1 Vasodilator Therapy
- •15.2.2 Calcium Channel Blockers
- •15.2.3 Adrenergic Blockers
- •15.2.4 Nitrates
- •15.2.5 Phosphodiesterase Inhibitors
- •15.2.6 Prostacyclins
- •15.2.7 Other Agents
- •15.3 Surgical Options
- •15.3.1 Sympathectomies
- •15.3.2 Management of Critical Digital Ischemia
- •References
- •16.1 Dysphagia
- •16.3 Chronic Gastritis
- •16.5 Association with Celiac Disease
- •16.6 Intestinal Vasculitis
- •16.7 Other Intestinal Diseases
- •16.8 Conclusion
- •References
- •17.1 Introduction
- •17.2 Primary Biliary Cirrhosis (PBC)
- •17.2.2 Similarities, Differences, and Overlap Among SS and PBC
- •17.2.3 Epithelium Involvement
- •17.2.4 Animal Models
- •17.2.5 Histology and Serology
- •17.3 Autoimmune Hepatitis (AIH)
- •17.4 Hepatitis C Virus (HCV) Infection and Sicca Syndrome
- •17.5 Algorithm for the Diagnosis of Liver Involvement in SS
- •References
- •18.1 Introduction
- •18.3 Involvement of the Pancreas in SjS
- •18.3.1 Clinical Presentation
- •18.3.2 Autoantibodies
- •18.3.3 Pancreatic Enzymes
- •18.3.4 Pathology
- •18.3.5 Imaging Studies of the Pancreas
- •18.4 Autoimmune Pancreatitis
- •18.4.1 Introduction
- •18.4.2 Clinical Features
- •18.4.3 Imaging
- •18.4.4 Serology
- •18.4.5 Pathology
- •18.4.6 Diagnostic Criteria
- •18.5.1 Introduction
- •18.5.2 Nomenclature
- •18.5.3 Clinical Manifestations
- •18.5.4 Serological Issues
- •18.5.5 Pathology
- •18.5.6 Diagnostic Criteria
- •18.6 Conclusions
- •References
- •19.1 Introduction
- •19.2 Interstitial Nephritis in Primary Sjögren’s Syndrome
- •19.2.1 Historical Aspects
- •19.2.2 Clinical Features
- •19.2.3 Histology
- •19.2.4 Pathogenesis
- •19.2.5 Differential Diagnosis
- •19.2.6 Treatment
- •19.3 Glomerulonephritis in Primary Sjögren’s Syndrome
- •19.3.1 Historical Aspects
- •19.3.2 Clinical Features
- •19.3.3 Histology
- •19.3.4 Pathogenesis
- •19.3.5 Differential Diagnosis
- •19.3.6 Treatment
- •19.4 Painful Bladder Syndrome/Interstitial Cystitis and Primary Sjögren’s Syndrome
- •19.4.1 Historical Aspects
- •19.4.2 Clinical, Cytoscopic, and Histologic Features
- •19.4.3 Pathogenesis and Association with Sjögren’s Syndrome
- •19.4.4 Differential Diagnosis
- •19.4.5 Treatment
- •References
- •20.2 Cerebral Lesions
- •20.3 Differential Diagnosis with Multiple Sclerosis, Neuromyelitis Optica, and Antiphospholipid Syndrome
- •20.4 Cranial Nerve Involvement
- •20.5 Diagnostic Algorithm of SS Patient with CNS Lesions, Myelitis, Meningitis
- •References
- •21.3 Sensorimotor Demyelinating Polyneuropathy (CIDP)
- •21.4 Multiple Mononeuropathy or Mononeuritis Multiplex
- •21.5 Sensory Ataxic Neuronopathy
- •21.6 Small Fiber Painful Sensory Neuropathy
- •21.7 Restless Leg Syndrome
- •References
- •22.1 Introduction
- •22.2 Pathogenesis of Autonomic Dysfunction in pSS
- •22.3 Diagnostic Tests
- •22.4 Parasympathetic and Sympathetic Disorders
- •22.4.1 Secretomotor Disorder
- •22.4.2 Urinary Disorder
- •22.4.3 Gastrointestinal Disorder
- •22.4.4 Pupillomotor Disorder
- •22.4.5 Orthostatic Intolerance
- •22.4.6 Vasomotor Disorder
- •22.5 Diagnostic Algorithm of pSS Patient with Autonomic Dysfunction
- •22.6 Treatment
- •References
- •23.1 Introduction
- •23.5 Prolactin and Sjögren Syndrome
- •23.7 Perspectives of Hormonal Treatment on Sjögren Syndrome
- •23.8 Conclusions
- •References
- •24.1 Introduction
- •24.2 Gynecological Manifestations in Sjögren’s Syndrome
- •24.3.1 Epidemiology and Clinical Features of NLS and Congenital Heart Block (CHB)
- •24.3.2 Maternal and Fetal Outcomes in NLS
- •24.3.3 Diagnosis
- •24.3.4 Risk Factors
- •24.3.5 Pathogenesis of Congenital Heart Block
- •References
- •25.1 Introduction
- •25.2 Serum Proteins
- •25.2.1 Acute Phase Reactants
- •25.2.2 Gammaglobulins
- •25.2.2.1 Polyclonal Hypergammaglobulinemia
- •25.2.2.3 Circulating Monoclonal Immunoglobulins
- •25.3 Hematological Abnormalities
- •25.3.1 Normocytic Anemia
- •25.3.2 Autoimmune Hemolytic Anemia
- •25.3.3 Aplastic Anemia
- •25.3.4 Pure Red Cell Aplasia
- •25.3.5 Myelodysplasia
- •25.3.6 Pernicious Anemia
- •25.3.7 Leukopenia
- •25.3.8 Lymphopenia
- •25.3.9 Neutropenia
- •25.3.10 Eosinophilia
- •25.3.11 Thrombocytopenia
- •25.4 Conclusions
- •References
- •26.2 Questionnaires
- •26.3 Ocular Tests
- •26.3.1 Schirmer Test
- •26.3.2 Vital Dyes
- •26.3.3 Rose Bengal
- •26.3.4 Fluorescein
- •26.3.5 Lissamine Green
- •26.3.7 Tear Osmolarity
- •26.3.8 Tear Meniscus
- •26.3.9 Tear Proteins
- •26.3.10 Ferning Test
- •26.3.11 Ocular Cytology
- •26.4 Oral Tests
- •26.4.1 Wafer Test
- •26.4.2 Whole Saliva Flow Collection
- •26.4.3 Saxon Test
- •26.4.5 Impression Cytology
- •26.5 Conclusion
- •References
- •27.1 Salivary Scintigraphy
- •27.2 Sialography
- •27.3 Ultrasound
- •27.4 Tomography
- •27.5 Magnetic Resonance
- •27.6 Salivary Gland Biopsy
- •27.6.1 Labial Gland Biopsy
- •27.6.2 Daniels’ Technique
- •27.6.3 Punch Biopsy
- •27.6.4 Major Salivary Gland Biopsy
- •27.6.5 Lacrimal Gland Biopsy
- •27.6.6 Focus Score
- •27.7 Is There an Alternative to Labial Salivary Gland Biopsy?
- •References
- •28.1 Antinuclear Antibodies
- •28.3 Antibodies Against Nonnuclear Antigens
- •28.7 Antiphospholipid Antibodies
- •28.9 Anticentromere Antibodies
- •28.12 Rheumatoid Factor and Cryoglobulins
- •28.13 Complement
- •28.14 Conclusion
- •References
- •29.1 Introduction
- •29.2 Historical Overview and Sets of Criteria
- •29.3 Preliminary European Criteria
- •References
- •30.1 Introduction
- •30.2 Clinical and Serological Peculiarities of Sjögren’s Syndrome
- •30.3 Assessment of Disease Activity or Damage in Systemic Autoimmune Diseases
- •30.4 Methodological Procedures to Develop Disease Status Criteria
- •30.5 Development of Disease Status Indices for Sjögren’s Syndrome
- •30.5.1 The Italian Approach
- •30.5.2 The British Approach
- •30.5.3 The EULAR Initiative
- •References
- •31.1 Introduction
- •31.3 Other Generic QoL/HRQoL Measures
- •31.6 Predictors of QoL and HRQoL (WHOQoL) in PSS
- •31.7 Therapeutic Interventions
- •31.8 Conclusions and Summary
- •References
- •32.1 Introduction
- •32.2 SS Associated with Systemic Lupus Erythematosus (SLE)
- •32.3 SS Associated with Rheumatoid Arthritis (RA)
- •32.5 SS Associated with Other Systemic Autoimmune Diseases
- •32.5.1 Mixed Connective Tissue Disease
- •32.5.2 Systemic Vasculitis
- •32.5.3 Antiphospholipid Syndrome (APS)
- •32.5.4 Sarcoidosis
- •32.6.1 SS Associated with Autoimmune Thyroiditis
- •32.6.2 SS Associated with Autoimmune Liver Disease
- •32.6.3 Association of SS with Coeliac Disease
- •32.7 Conclusions
- •References
- •33.1 Introduction
- •33.2 Methodological Considerations
- •33.3 Primary Sjögren’s Syndrome and Lymphoma
- •33.3.1 Risk Levels
- •33.3.2 Lymphoma Subtypes
- •33.4 Prediction of Lymphoma
- •33.4.1 Can We Tell Who Will Develop Lymphoma and When This May Occur?
- •33.4.2 Established Risk Factors
- •33.4.3 Recently Proposed Newer Risk Factors
- •33.5 Pathogenetic Mechanisms
- •33.6 Medication and Risk of Lymphoma in SS
- •33.7 Associated Sjögren’s Syndrome and Lymphoma
- •33.8 Other Cancers in SS
- •33.9 Conclusion
- •References
- •34.1 Introduction
- •34.2 Mortality and Causes of Death in pSS
- •34.4 Conclusions
- •References
- •35.1 Introduction
- •35.2 General Considerations
- •35.3.1 Keratoconjunctivitis Sicca
- •35.3.2 Xerostomia
- •35.3.3 Systemic Dryness
- •35.3.4 Extraglandular Manifestations
- •35.4 Diagnosis
- •35.4.2 Diagnostic Methods
- •35.4.2.1 Keratoconjunctivitis Sicca
- •35.4.2.2 Xerostomia
- •35.4.2.3 Salivary Gland Biopsy
- •35.4.2.4 Immunological Tests
- •35.4.2.5 Other Laboratory Findings
- •35.5 Comorbidities and Occupational Disability
- •35.6 Treatment
- •35.6.1 Keratoconjunctivitis Sicca
- •35.6.2 Xerostomia
- •35.6.3 Management of Extraglandular Features
- •35.7 When to Refer to a Specialist
- •References
- •36.1 Background
- •36.2 General Approach to Dry Mouth
- •36.3 Additional Dental Needs of the SjS Patient
- •36.3.1 Background
- •36.4 Particular Oral Needs of the SjS Patient to Be Assessed by the Rheumatologist
- •36.5 Use of Secretagogues
- •36.5.1 Other Cholinergic Agonists
- •36.5.2 Additional Topical Treatments
- •36.5.3 Systemic Therapy
- •36.6 Oral Candidiasis
- •36.7 Treatment and Management of Cutaneous Manifestations
- •36.7.1 Treatment of Dry Skin in SjS Is Similar to Managing Xerosis in Other Conditions
- •36.7.2 Vaginal Dryness
- •36.7.3 Special Precautions at the Time of Surgery
- •References
- •37.1 Introduction
- •37.2 Marginal Zone (MZ) Lymphomas
- •37.2.1 Extranodal Marginal Zone Lymphomas of MALT Type
- •37.2.2 Therapeutic Approaches of MALT Lymphomas
- •37.2.4 Managing NMZL
- •37.3.1 Histology and General Considerations
- •37.3.2 Treatment of DLBCL
- •37.4 Conclusions
- •References
- •38.1 Introduction
- •38.2 Antimalarials
- •38.4 Glucocorticoids
- •38.5 Azathioprine
- •38.6 Cyclophosphamide
- •38.7 Methotrexate
- •38.8 Cyclosporine
- •38.9 Conclusion
- •References
- •39.3 Mycophenolic Acid
- •39.4 Mizoribine
- •39.5 Rebamipide
- •39.6 Diquafosol
- •39.7 Cladribine
- •39.8 Fingolimod
- •References
- •40.1.2.1 Serum BAFF in SS
- •40.1.3 BAFF Is Secreted by Resident Cells of Target Organs of Autoimmunity
- •40.2 Rituximab in SS
- •40.2.1 The Different Studies Assessing Rituximab in SS
- •40.2.2 Safety of Rituximab
- •40.2.3 Increase of BAFF After Rituximab Therapy
- •40.3.1 Epratuzumab
- •40.4 Conclusion
- •References
- •41.1 Introduction
- •41.2 Cytokine Targeted Therapies
- •41.2.2 Etanercept
- •41.2.3 Interferon Alpha
- •41.2.4 Emerging Anticytokine Therapies
- •41.3 T Cell Targeted Therapies
- •41.3.1 Efalizumab
- •41.3.2 Alefacept
- •41.3.3 Abatacept
- •41.4 Conclusion
- •References
- •42.1 Introduction
- •42.2 Progression and Disease Activity in SjS
- •42.2.1 Saliva
- •42.2.2 Serum
- •42.2.3 Labial or Parotid Tissue
- •42.3 Molecular Targets for Potential Therapeutic Interventions
- •42.3.1 Interferons
- •42.3.2 Cytokines
- •42.3.3 B Cell Activating Factors
- •42.3.4 B and T Cell Receptors
- •42.3.4.1 Rituximab
- •42.3.4.2 Epratuzumab
- •42.3.4.3 Abatacept
- •42.4 Gene Therapy
- •42.5 Stem Cell Therapy
- •42.6 Conclusion
- •References
- •Index
11 Non-Vasculitic Cutaneous Involvement |
161 |
be encountered varies between primary and secondary SjS. In addition, there is significant ethnic variation in patterns of skin disease seen in SjS. For example, the autoimmune annular erythema seen in Japanese SjS patients is extremely rare in patients from North America. Similarly, SCLE, a common skin feature among North American SjS patients, is unusual in SjS patients from Japan.
11.3Skin Changes Encountered in Primary SjS
Xerosis of both cutaneous and mucosal surfaces is a key manifestation of SjS [7]. Cutaneous xerosis may be characterized both on the basis of subjective symptoms (dryness, pinprick sensation) and objective findings (fine, dry scale; loss of light reflection from the skin surface; increased transepidermal water loss) [4]. Patients may report dryness and loss of luster of hair, as well as dryness and brittleness of the nails [1].
Cutaneous xerosis is generally reported in half to two-thirds of cases of SjS. In their classic paper, Bloch et al. [8] reported that 33/62 patients (53%) complained of dryness of the skin. Bernacchi et al. observed xerosis in 34/62 patients (55%) with primary SjS and found xerosis to be significantly higher in primary as opposed to secondary SjS [4]. In that study, patients with xerosis tended to be older (mean age 65 vs. 50) and were more likely to have circulating anti-Ro/SS-A or anti-La/ SS-B antibodies [4]. Skin dryness and pruritus are very common among healthy senior and elderly individuals who do not have SjS. Because SjS patients are often older than the mean population age, data describing the prevalence of dryness and pruritus in SjS should be viewed in this context.
The pathogenesis of xerosis in SjS is not completely understood. Dysfunction of the sebaceous and eccrine glands has been suggested because these organs are responsible for intrinsic skin lubrication [1]. A lymphohistocystic infiltrate within the eccrine glands has been demonstrated in some cases [1], supporting the hypothesis of loss of function secondary to an immune-mediated inflammatory process. However, a quantitative study of 12 patients with SjS (3 primary, 9 secondary), including eight patients who complained specifically of xerosis, failed to show diminished pilocarpine-induced sweat production compared to controls [9].
Altered function of the autonomic nervous system, both sympathetic and parasympathic, has been reported in SjS. Kovacs et al. reported a blunted response to cholinergic stimulation in SjS patients [10]. Mandl et al. reported abnormal responses for cutaneous vasoconstriction, orthostatic blood pressure, and deep breathing in patients with SjS compared to controls [11]. Xerosis in SjS may also relate to alterations in barrier function of the stratum corneum and to an altered keratinocyte pro- tein-expression profile [12].
The human stratum corneum plays a major role in limiting preventing transepidermal water loss and desiccation of the skin. However, there has been very little research on the biochemical integrity of the stratum corneum in SjS patients.
162 |
H.W. Walling and R.D. Sontheimer |
11.3.1Pruritus
Xerosis is often accompanied by pruritus. Pruritus was reported in 26/62 patients (42%) with primary SjS and associated with xerosis in 19 (73%) of those with pruritus [4]. Chronic rubbing and scratching may lead to hyperpigmentation and lichenification [1, 7, 13]. When pruritus is particularly intense, other incidental causes should be addressed (e.g., dermatitis herpetiformis, dermatographic urticaria, prodromal pemphigoid, and eczematous drug eruptions) [1].
Treatment of xerosis and pruritus in SjS can be challenging [1]. For xerosis, limiting daily bathing to 5–10 min with lukewarm (rather than hot) water can be helpful. Heat tends to soften and liquefy the natural skin oils, making them more likely to be removed by soapy water while bathing. Mild soaps or soapless cleansers should be used to cleanse dry areas such as the arms and legs while bathing. Strong antibacterial soaps and surgical scrubs (chlorhexidine) should be reserved for cleansing the body fold areas. Liquid body scrubs should be avoided while bathing. Colloidal oatmeal added to bath water can be soothing for dry, itchy skin.
After bathing, the patient should be directed to gently pat off excess water with a towel and to apply a bland emollient cream or ointment to damp skin. The emollient should be reapplied during the day as often as necessary and practical. When significant pruritus is present, topical corticosteroids (e.g., hydrocortisone, triamcinolone, fluocinonide, or clobetasol, in increasing order of potency) may be applied in ointments or creams once or twice daily for up to 2-week intervals. Ointments are preferred to creams because they trap water in the skin more effectively and are therefore more moisturizing. Nonsteroidal topical immunomodulators (tacrolimus, pimecrolimus) may be useful [14]. Oral antihistamines may provide relief of pruritis for some patients.
Caution should be observed with over-the-counter products alleged to treat dry skin. Ingredients such as neomycin and diphenhydramine (in rub-on or spray-on itch relief products) can cause cutaneous allergic reactions, often resulting in worsening of the itching and confusion about the correct diagnosis.
Two manifestations of SjS merit particular attention: eyelid dermatitis and angular cheilitis. Both commonly occur in association with regional mucosal dryness, though the cutaneous findings may not be attributably only to the xerophthalmia and xerostomia.
11.3.2Annular Erythema of SjS
Annular erythema of SjS is comprised of erythematous skin lesions with indurated borders. These generally occur on the upper body and display mononuclear infiltrates in perivascular and periappendageal regions on skin biopsy. Annular erythema was first linked with primary SjS in Japanese patients in the 1980s [15]. This skin lesion was associated with the presence of circulating anti-Ro/SS-A and anti-La/SS-B autoantibodies but lacked the prominent interface dermatitis usually demonstrated by
11 Non-Vasculitic Cutaneous Involvement |
163 |
Fig. 11.2 Annular erythema of SjS. These skin lesions are from the left thigh and palm of a 40-year-old Filipino woman with a history of parotid swelling, sicca symptoms, and arthralgias. She had a positive antinuclear antibody assay (1:640, speckled pattern) and anti-Ro/SS-A and anti-La/SS-B autoantibodies were present. Double-stranded DNA antibody assay was negative. The recurrent annular skin lesions with overlying mild scale that are shown had skin biopsy findings that were consistent with annular erythema of SjS. A mild degree of interface dermatitis on biopsy was likely responsible for the mild clinical scaling shown in the photos (potassium hydroxide exam of scraped scale was negative for dermatophytes). In addition to the upper trunk, neck and face, annular erythema of SjS skin lesions have also been described on the palms and soles (Clinical images were kindly provided by Dr. Jan P. Dutz, Department of Dermatology, University of British Columbia, Canada)
subacute cutaneous lupus erythematosus (SCLE). Moreover, SCLE lesions are quite rare among Japanese individuals. Annular erythema occurs in Caucasian SjS patients only rarely. Debate has existed about a potential relationship between annular erythema of SjS and SCLE. Some authors have speculated that annular erythema of SjS is the Japanese equivalent of lupus tumidus skin lesions in Westerners.
Katayama et al. have recently analyzed the clinical and laboratory findings in 28 of their own SjS patients with annular erythema. These cases were identified from a Japanese Dermatology Department and combined with data abstracted from 92 previously published cases [15]. Three clinical types of annular erythema have been identified: a doughnut-shaped, ring-like erythema with elevated borders: an SCLElike marginally scaled, polycyclic erythema; and a papular insect bite-like erythema. Each of the three morphologies displays the same set of histopathologic changes. In addition to the upper extremities and face, annular erythema has also been described on the soles of the feet (Fig. 11.2).
Three quarters of the annular erythema patients reported by Katayama et al. had circulating anti-Ro/SS-A and anti-La/SS-B autoantibodies. However, the presence
164 |
H.W. Walling and R.D. Sontheimer |
of annular erythema did not portend the occurrence of any specific SjS manifestations or complications. Annular erythema is very sensitive to systemic glucocorticoids and is typically controlled effectively with prednisone 10 mg/day.
11.3.3Eyelid Dermatitis
Eyelid dermatitis, common in SjS, can affect the upper or lower eyelids and is associated with pruritus or a foreign-body sensation. Three patterns of eyelid dermatitis are described: the slightly lichenified; the moderately lichenified and papular; and eyelid edema [13]. In a study of 52 Japanese patients with primary SjS, 22 (42%) had eyelid dermatitis. Patients with eyelid dermatitis tended to be older (mean age 61 vs. 49) and complain of ocular dryness (86% vs. 59%).
A study from Italy reported a somewhat lower prevalence of eyelid dermatitis among SjS patients [4]. Approximately equal percentages of primary and secondary SjS patients were described as having this condition: 15 of 62 patients (24%) and 8 of 31 (26%) patients, respectively. Of the patients with primary SjS, eyelid dermatitis was commonly associated with xerosis (13/15; 87%) and sicca symptoms (14/15; 93%). Only upper eyelid involvement was reported in this study.
Eyelid dermatitis may be managed with the intermittent use of low potency topical steroid creams (e.g., hydrocortisone, desonide). Nonsteroidal topical immunomodulators such as tacrolimus (0.03% or 0.1% ointment) and pimecrolimus (1% cream) are also useful.
Angular cheilitis. The xerostomia of SjS is associated with a number of intraoral consequences. These include a diminished rate of saliva secretion; a decreased buffering capacity of saliva; an increased risk of colonization by Candida, lactobacillus, or streptococcus species; and increased rates of dental caries [16, 17].
Angular cheilitis is a sign commonly associated with oral candidiasis. Both angular cheilitis and oral candidiasis have been correlated with the diminished salivary flow seen in SjS [17]. About a third of SjS patients will have difficulty with angular cheilitis.
A study from Italy found angular cheilitis to be more prevalent in patients with primary SjS (24/62; 39%) compared to secondary SjS (5/31; 16%). More than 95% of cases were associated with xerostomia [4].
Investigators from Sweden reported erythema or fissuring at the angles of the mouth in 28 (70%) of 40 patients with primary SjS and angular cheilitis in 14 (35%) of those same patients. In contrast, angular cheilitis is estimated to occur in about 3–5% of the general population [16].
In a study of 50 patients with SjS, three quarters were diagnosed with oral candidiasis and angular cheilitis was present in approximately one-fourth [18]. Oral candidiasis is more common in patients taking certain medicines such as prednisone or other immunosuppressives.
Angular cheilitis may be managed with topical antimycotic ointments (e.g., ketoconazole, miconazole, clotrimazole, or nystatin). Measures to increase salivary
